Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease.
- Published in:
- CNS Drugs, 2022, v. 36, n. 4, p. 365, doi. 10.1007/s40263-022-00915-3
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 4
Results: 7
1
2
Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 4, p. 345, doi. 10.1007/s40263-022-00911-7
- By:
- Publication type:
- Article
3
Risdiplam: A Review in Spinal Muscular Atrophy.
- Published in:
- CNS Drugs, 2022, v. 36, n. 4, p. 401, doi. 10.1007/s40263-022-00910-8
- By:
- Publication type:
- Article
4
Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study.
- Published in:
- CNS Drugs, 2022, v. 36, n. 4, p. 389, doi. 10.1007/s40263-022-00909-1
- By:
- Publication type:
- Article
5
Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?
- Published in:
- CNS Drugs, 2022, v. 36, n. 4, p. 315, doi. 10.1007/s40263-022-00906-4
- By:
- Publication type:
- Article
6
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.
- Published in:
- CNS Drugs, 2022, v. 36, n. 4, p. 377, doi. 10.1007/s40263-022-00904-6
- By:
- Publication type:
- Article
7
Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.
- Published in:
- CNS Drugs, 2022, v. 36, n. 4, p. 327, doi. 10.1007/s40263-022-00903-7
- By:
- Publication type:
- Article